Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Core Insights - Iovance Biotherapeutics, Inc. has appointed Dan Kirby as the Chief Commercial Officer to enhance its commercial strategy and market presence [1][2][3] - The company aims to expand the U.S. launch of its TIL therapy, Amtagvi, and grow Proleukin sales while preparing to enter new international markets [2][3] Company Overview - Iovance Biotherapeutics focuses on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients [1][3] - The company is recognized as a leader in TIL cell therapy, with Amtagvi being the first FDA-approved T cell therapy for a solid tumor indication [3] Leadership Background - Dan Kirby has extensive experience in cell therapy commercialization, having previously held leadership roles at Orca Bio, Omeros Corporation, and Celgene [2] - His expertise includes market access, reimbursement, and marketing strategies for cell and gene therapies [2]